Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 1526 Print this page  Email this page Small font size Default font size Increase font size
Year : 2007  |  Volume : 22  |  Issue : 1  |  Page : 13-16

Value of indium-111 octreotide scintigraphy in neuroendocrine tumors

Department of Nuclear medicine, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi-110060, India

Correspondence Address:
Anjali Jain
Department of Nuclear Medicine, Sir Ganga Ram Hospital, New Delhi-110060
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Somatostatin receptors are over expressed in several neuroendocrine tumors making these receptors potential targets for radionuclide diagnosis and therapy. Indium-111 - DTPA octreotide is a somatostatin analog that has been used for detecting somatostatin receptor positive tumors for years. Somatostatin receptor scintigraphy and octreotide therapy have changed the management of neuroendocrine tumors. The object of this report is to highlight the role of radionuclide scintigraphy and therapy in neuroendocrine tumors.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded116    
    Comments [Add]    

Recommend this journal